ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,939.42
      -1.63%
      US Tech 100
      20,762.04
      -1.99%
      Dow Jones
      42,809.03
      -1.19%
      Brent Oil
      73.445
      0.76%
      Bitcoin
      94,026.81
      -1.73%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Viridian Therapeutics Inc (VRDN)

      7. Viridian Therapeutics Inc (VRDN) News

      Viridian Therapeutics Inc

      Viridian Therapeutics Inc (VRDN)

      Viridian Metals Inc
      19.17
      -0.66
      ( -3.33% )
      Updated: 11:59:12
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      VRDN News

      Official News Only

      Form 8-K - Current report
      Edgar (US Regulatory)
      December 16 2024
      VRDN (-3.33%)

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
      Edgar (US Regulatory)
      November 14 2024
      VRDN (-3.33%)

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
      Edgar (US Regulatory)
      November 14 2024
      VRDN (-3.33%)

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
      Edgar (US Regulatory)
      November 14 2024
      VRDN (-3.33%)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      Edgar (US Regulatory)
      November 12 2024
      VRDN (-3.33%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      November 12 2024
      VRDN (-3.33%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      September 30 2024
      VRDN (-3.33%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      September 30 2024
      VRDN (-3.33%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      September 17 2024
      VRDN (-3.33%)

      Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
      Edgar (US Regulatory)
      September 17 2024
      VRDN (-3.33%)

      VRDN Discussion

      View Posts
      Monksdream Monksdream 3 months ago
      VRDN more upside possible

      👍️0
      it_happens it_happens 4 months ago
      Touched 20s today. Maybe it will stay above 20 tomorrow
      👍️0
      power11 power11 4 months ago
      LOW 20'S BY WEEKEND IMO !!!
      GOOD LUCK
      👍️0
      it_happens it_happens 4 months ago
      Good news. I don't think that this is merely a one-day runner.
      👍️0
      power11 power11 4 months ago
      BTIG RESEARCH ADJUST PRICE TARGET TO 56 FROM 46; STRONG BUY !!
      👍️0
      it_happens it_happens 4 months ago
      Over 15 and having a good day today
      👍️0
      Monksdream Monksdream 4 months ago
      VRDN under $15
      👍️0
      Apprentice Apprentice 3 years ago
      I put into it a lot of $
      423 shares!
      👍️0
      Apprentice Apprentice 3 years ago
      It just doesn't want to move above $18
      Yet, it's not diving much either.
      What do you think at this point? Sell temporarily and by later low?
      My average is too high @17.76 !
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Viridian Therapeutics, Inc., formerly Miragen Therapeutics, Inc., is a biotechnology company. The Company is engaged in developing multiple product candidates to treat patients who suffer from thyroid eye disease (TED), a debilitating orphan disease, and has early-stage programs focused on other targets and indications. Its lead candidate, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody (mAb) that is under development for thyroid eye disease (TED). The Company's TED pipeline also includes VRDN-002 and VRDN-003. Its other programs include VRDN-004, which is under development for undisclosed rare orphan disease, and VRDN-005, which is under development for tick-borne disease (TBD). The Company also out licenses its programs.
      👍️0

      Your Recent History

      NASDAQ
      VRDN
      Viridian Therapeutics
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads